Director/PDMR Shareholding
20 December, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transactions by persons discharging managerial responsibilities
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | Susan Kilsby | ||
| 2. | Reason for the notification | |||
| a) | Position / status | Chairman – PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”) | ||
| Identification code | ISIN: US82481R1068 | |||
| b) | Nature of the transaction | Acquisition of ADSs, being the part of Ms. Kilsby’s total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| $ | 168.0470 | 164 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | December 19, 2018 | ||
| f) | Place of the transaction | XNAS / XBOS / ARCX | ||
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | Olivier Bohuon | ||
| 2. | Reason for the notification | |||
| a) | Position / status | Senior Independent Director - PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc Ordinary Shares of 5 pence each (“Ordinary Shares”) | ||
| Identification code | ISIN: JE00B2QKY057 | |||
| b) | Nature of the transaction | Acquisition of Ordinary Shares, being the part of Mr. Bohuon’s total fees that are paid in Ordinary Shares for the period of service from October 1 to December 31, 2018. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| £ | 44.31 | 140 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | December 19, 2018 | ||
| f) | Place of the transaction | LSE (TRQX) | ||
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | Ian Clark | ||
| 2. | Reason for the notification | |||
| a) | Position / status | Non-Executive Director - PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”) | ||
| Identification code | ISIN: US82481R1068 | |||
| b) | Nature of the transaction | Acquisition of ADSs, being the part of Mr. Clark’s total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| $ | 168.0470 | 44 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | December 19, 2018 | ||
| f) | Place of the transaction | XNAS / XBOS / ARCX | ||
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | Gail Fosler | ||
| 2. | Reason for the notification | |||
| a) | Position / status | Non-Executive Director - PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”) | ||
| Identification code | ISIN: US82481R1068 | |||
| b) | Nature of the transaction | Acquisition of ADSs, being the part of Ms. Fosler’s total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| $ | 168.0470 | 47 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | December 19, 2018 | ||
| f) | Place of the transaction | XNAS / XBOS / ARCX | ||
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | Steven Gillis | ||
| 2. | Reason for the notification | |||
| a) | Position / status | Non-Executive Director - PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”) | ||
| Identification code | ISIN: US82481R1068 | |||
| b) | Nature of the transaction | Acquisition of ADSs, being the part of Dr. Gillis’ total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| $ | 168.0470 | 49 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | December 19, 2018 | ||
| f) | Place of the transaction | XNAS / XBOS / ARCX | ||
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | David Ginsburg | ||
| 2. | Reason for the notification | |||
| a) | Position / status | Non-Executive Director - PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”) | ||
| Identification code | ISIN: US82481R1068 | |||
| b) | Nature of the transaction | Acquisition of ADSs, being the part of Dr. Ginsburg’s total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| $ | 168.0470 | 44 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | December 19, 2018 | ||
| f) | Place of the transaction | XNAS / XBOS / ARCX | ||
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | Sara Mathew | ||
| 2. | Reason for the notification | |||
| a) | Position / status | Non-Executive Director - PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”) | ||
| Identification code | ISIN: US82481R1068 | |||
| b) | Nature of the transaction | Acquisition of ADSs, being the part of Ms. Mathew’s total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| $ | 168.0470 | 46 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | December 19, 2018 | ||
| f) | Place of the transaction | XNAS / XBOS / ARCX | ||
| 1. | Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) | |||
| a) | Name | Albert Stroucken | ||
| 2. | Reason for the notification | |||
| a) | Position / status | Non-Executive Director - PDMR | ||
| b) | Initial notification / amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Shire plc | ||
| b) | LEI | 54930005LQRLI2UXRQ59 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument | Shire plc American Depositary Shares (“ADSs”) | ||
| Identification code | ISIN: US82481R1068 | |||
| b) | Nature of the transaction | Acquisition of ADSs, being the part of Mr. Stroucken’s total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018. | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| $ | 168.0470 | 63 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||
| e) | Date of the transaction | December 19, 2018 | ||
| f) | Place of the transaction | XNAS / XBOS / ARCX | ||
Sarah Rixon
Senior Company Secretarial Assistant
For further information please contact:
| Investor Relations | ||
| Christoph Brackmann | christoph.brackmann@shire.com | +41 41 288 41 29 |
| Sun Kim | sun.kim@shire.com | +1 617 588 8175 |
| Scott Burrows | scott.burrows@shire.com | +41 41 288 4195 |
| Media | ||
| Katie Joyce | kjoyce@shire.com | +1 781 482 2779 |
NOTES TO EDITORS
About Shire
Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.
Championing patients is our call to action - it brings the opportunity - and responsibility - to change people’s lives.